Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening
Shifali Shishodia ; Raymundo Nu?ez ; Brayden P. Strohmier , et al. J. Med. Chem.,2022,65(20):13714-13735. DOI: 10.1021/acs.jmedchem.2c00864 PubMed ID: 36227159
More
Abstract: PBRM1 is a subunit of the PBAF chromatin remodeling complex that uniquely contains six bromodomains. PBRM1 can operate as a tumor suppressor or tumor promoter. PBRM1 is a tumor promoter in prostate cancer, contributing to migratory and immunosuppressive phenotypes. Selective chemical probes targeting PBRM1 bromodomains are desired to elucidate the association between aberrant PBRM1 chromatin binding and cancer pathogenesis and the contributions of PBRM1 to immunotherapy. Previous PBRM1 inhibitors unselectively bind SMARCA2 and SMARCA4 bromodomains with nanomolar potency. We used our protein-detected NMR screening pipeline to screen 1968 fragments against the second PBRM1 bromodomain, identifying 17 hits with Kd values from 45 μM to >2 mM. Structure–activity relationship studies on the tightest-binding hit resulted in nanomolar inhibitors with selectivity for PBRM1 over SMARCA2 and SMARCA4. These chemical probes inhibit the association of full-length PBRM1 to acetylated histone peptides and selectively inhibit growth of a PBRM1-dependent prostate cancer cell line.
Purchased from AmBeed: 77326-36-4 ; 104-87-0 ; 2148-56-3 ; 63329-53-3 ; 1591-37-3 ; 387-45-1 ; 936-08-3 ; 1123-56-4 ; 2819989-75-6 ; 703-80-0 ; 1885-29-6 ; 115643-59-9 ; 15764-16-6 ; 487-68-3 ; 145737-61-7 ; 5779-95-3 ; 88-68-6 ; 6575-11-7 ; 77326-62-6 ; 88-65-3 ; 4635-59-0 ; 5779-94-2 ; 56043-01-7 ; 5779-93-1 ; 1591-38-4 ; 446-52-6 ; 62803-47-8 ; 1885-31-0 ; 620-23-5 ; 54166-95-9 ; 22179-72-2 ; 529-20-4 ; 100-52-7 ; 123-11-5 ; 1711-06-4 ; 454-89-7 ; 170875-01-1 ; 883032-29-9 ; 2819989-61-0 ; 1915012-21-3 ; 2819989-58-5 ; 2819989-60-9 ; 2819989-57-4 ; 2819989-68-7 ; 2819989-67-6 ; 111478-13-8 ; 73096-42-1 ; 2835-78-1 ; 118-92-3 ; 22458-07-7 ; 80258-99-7 ; 24782-64-7 ; 1108790-90-4 ; 175204-03-2 ; 97-96-1 ; 780802-33-7 ; 89-98-5 ...More
CAS No. : | 88-65-3 | MDL No. : | MFCD00002402 |
Formula : | C7H5BrO2 | Boiling Point : | - |
Linear Structure Formula : | (Br)C6H4(COOH) | InChI Key : | XRXMNWGCKISMOH-UHFFFAOYSA-N |
M.W : | 201.02 | Pubchem ID : | 6940 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
2-Bromobenzoic acid (CAS: 88-65-3) can be used in the preparation of Salicylic acid (CAS: 69-72-7). Salicylic acid exhibits bacteriostatic, fungicidal, and keratolytic actions. Its salts, known as salicylates, are commonly used as analgesics.
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
52% | With copper(l) iodide; caesium carbonate In N,N-dimethyl-formamide at 110℃; for 24 h; | 1.00 g (4.97mmol) of 2-bromobenzoic acid 44, 2.00 g (9.95 mmol) of guanidine hydrochloride, 6.48 g (19.9 mmol) of cesium carbonate and 95 mg (0.497mmol) of copper(I) iodide were dissolved in 20 ml of abs. DMF and stirred at 110 °C for 24 h. The solvent was distilled off in vacuo and the residue filtered through a short pad of silica gel using methanol as eluent. After recrystallization from ethanol 717 mg (52percent) of 2-aminoquinazolone 10 were obtained as a colorless solid. Mp.: >300°C. 1H-NMR(250 MHz, DMSO-d6): / ppm = 10.95 (s, 1H, NH); 7.87 (dd,J =7.9 Hz,J =1.5 Hz, 1H, Ar-H); 7.55 (ddd,J =8.5 Hz,J =7.2 Hz,J =1.6 Hz; 1H, Ar-H); 7.19 (d,J =8.2 Hz, 1H, Ar-H); 7.09 (t,J =7.5 Hz, 1H, Ar-H); 6.34 (br, 2H, NH2). 13C-NMR(75.4 MHz, DMSO-d6): / ppm = 163.2, 152.4, 150.2, 133.9, 125.9, 123.1, 121.4, 117.1. IR: ν = 3581 (w); 3399 (m); 3147 (m); 3063 (m); 2642 (m); 1801 (w); 1689 (m); 1657 (m); 1633 (m); 1608 (s); 1575 (m); 1558 (m); 1511 (m); 1473 (s); 1451 (m); 1402 (m); 1340 (m); 1248 (m); 1166 (m); 1153 (m); 1123 (m); 1041 (m); 1018 (m); 897 (m); 785 (m); 764 (s); 716 (w); 680 (m);623 (m); 591 (m); 537 (s); 491 (m); 465 (m). Anal. calcd. for C8H7N3O*1/3H2O(167,1): C 57.50; H 4.62; N 25.15; found: C 57.65; H 4.41; N 25.30. |